
Each
year an estimated two million people die of liver disease. The World
Health Organization estimates that over 650 million people worldwide
are affected by some form of liver disease, including 30 million
Americans. China has the world’s largest population of Hepatitis
B patients (approx. 120 million) with 500,000 people dying of the
liver disease every year. On a worldwide base, 1-2 million deaths
are accounted to liver related diseases annually.
In the US alone, there are around 500,000 critical episodes of liver
problems requiring hospitalization with 80,000 deaths annually. Liver
transplantation is currently the only therapy proven to extend survival
but the waiting list for liver transplants is extensive and many
on the list will not receive an organ due to a dramatic shortage
of donors or not being eligible.
In 2007, there were nearly 17,000 individuals on the US waiting
list for a liver transplant. Only 30% of those in need were transplanted.
The average waiting time was more than 400 days. The same year, about
1,300 people died while waiting for a suitable donor with no medical
option for saving their life available. For those patients with fulminant
hepatic failure, a severe liver disease with 60-90% mortality, depending
on the cause, only 10% received a transplant. Liver transplantation
has a relatively high mortality of 30% -40% at 5 -8years with 65%
of the deaths occurring in the first 6 months. In addition, patients
who have undergone transplantation have to use lifelong immunosuppressive
therapy.
The need for a bioartificial liver device able to remove toxins and
improve survival results is more critical today than ever before. Limited
treatment options, a low number of donor organs, the high price of
transplants and follow up costs, a growing base of hepatitis, alcohol
abuse, drug overdoses, liver cancer and other factors, all clearly
indicate a strong need for a bioartificial liver device.
|
 |
|

Prevalence
of Liver Disease
(Worldwide)
|

Liver
Transplant Patients
(USA)
|
|
|